SEC Filing Summary
Filing identity: The supplied filing is Landec Corporation’s Form 10-K for the fiscal year ended May 26, 2013, filed August 6, 2013. It is not a Lifecore Biomedical filing and does not correspond to “2012 Q4” as stated in the request metadata. Lifecore Biomedical, Inc. is a wholly owned Landec subsidiary and reportable segment.
Business Context and Reporting Period
Landec develops and sells differentiated food packaging, fresh-cut and whole produce, food export products, and hyaluronan-based biomaterials. Its principal operating businesses are Apio’s Food Products Technology and Food Export segments and Lifecore’s HA-based Biomaterials segment. The fiscal year comprised the period ended May 26, 2013, compared primarily with the fiscal year ended May 27, 2012.
- Food Products Technology revenue: $320.4 million, up 54%, substantially reflecting a full year of GreenLine operations.
- Food Export revenue: $78.6 million, up 10%.
- HA-based Biomaterials revenue: $41.3 million, up 20%; ophthalmic products represented approximately 65% of Lifecore revenue and orthopedic products approximately 20%.
- Approximately 30% of total revenue came from international customers.
Key Financial Metrics
| Metric | FY2013 | FY2012 | Change |
|---|---|---|---|
| Total revenue | $441.7 million | $317.6 million | +39% |
| Gross profit | $62.8 million | $52.1 million | +20% |
| Gross margin | 14.2% | 16.4% | Down approximately 220 basis points |
| Operating income | $24.9 million | $14.6 million | +71% |
| Operating margin | 5.6% | 4.6% | Up approximately 100 basis points |
| Net income attributable to common stockholders | $22.6 million | $12.7 million | +78% |
| Diluted EPS | $0.85 | $0.49 | +73% |
| Cash flow from operations | $21.2 million | $22.2 million | Down 4% |
| Capital expenditures | $8.9 million | $5.4 million | Up 65% |
FY2013 net income included significant non-operating and non-cash items, including $8.1 million of income from the increase in the fair value of the Windset investment and a $3.9 million reversal of the GreenLine earn-out liability. Dividend income from Windset was $1.1 million.
Fourth-quarter FY2013 revenue was $107.1 million, gross profit was $13.0 million, and net income attributable to common stockholders was approximately $4.5 million, or $0.17 diluted EPS.
Liquidity, Debt and Balance Sheet
- Cash and cash equivalents declined to $13.7 million from $22.2 million.
- Marketable securities were $1.5 million at year-end.
- Total debt was approximately $44.3 million, including $4.0 million drawn on Apio’s revolving line of credit and $40.3 million of long-term debt before current classification.
- Total liabilities were $110.5 million and total stockholders’ equity was $178.7 million.
- Operating cash flow was largely offset by $10.4 million of investing outflows and $19.3 million of financing outflows.
- Major FY2013 financing uses included a $9.7 million Lifecore earn-out payment and $14.7 million of payments on credit lines and long-term debt.
- Management stated that cash, marketable securities and internally generated operating cash flow should be sufficient for operational and capital requirements for at least the next twelve months.
- Apio and Lifecore were in compliance with applicable financial covenants at May 26, 2013.
Material Changes Versus the Prior Comparable Period
- The April 2012 GreenLine acquisition contributed a full year of revenue in FY2013 versus only approximately $9.1 million of revenue in FY2012. The acquisition added approximately $86 million of FY2013 Food Products Technology revenue.
- Food Products Technology gross profit increased to $37.1 million from $25.2 million, while Lifecore gross profit increased to $19.1 million from $18.0 million.
- Apio SG&A increased 49%, primarily from GreenLine and additional sales and marketing costs; consolidated SG&A increased 23%.
- Corporate revenue fell 66% because the Monsanto license agreement terminated in FY2012. Monsanto license revenue was $2.7 million in FY2012 and zero in FY2013.
- Landec sold its seed subsidiary, Landec Ag, to INCOTEC for $600,000 in June 2012 and entered into related license and supply agreements.
- Apio’s Chiquita agreement reverted from exclusive to non-exclusive for 2013 after Chiquita elected not to maintain its exclusive license.
- Weather-related produce sourcing issues reduced FY2013 Food Products Technology operating income by approximately $5.0 million.
- The company reported and remediated a material weakness related to controls over periodic fair-value adjustments for its private-company investment. Management and Ernst & Young concluded that internal control over financial reporting was effective as of May 26, 2013.
Outlook, Risks and Unusual Items
The filing does not provide formal numerical revenue or earnings guidance. Management described growth opportunities from GreenLine cross-selling, expanded value-added produce products, new customers, Lifecore product approvals and aseptic filling services, but cautioned that results may fluctuate materially.
- Produce availability, crop prices, weather, disease and other agricultural conditions can affect volume, costs and margins.
- Customer concentration is significant: the top five customers represented approximately 40% of FY2013 revenue, and the two largest Food Products Technology customers represented approximately 16% and 13%.
- Several raw materials and services are single-source, creating supply-interruption risk.
- Operations depend on concentrated manufacturing facilities in Guadalupe, California and Chaska, Minnesota.
- Lifecore’s products are subject to FDA and foreign regulatory requirements, including potential 510(k) or PMA processes for certain products.
- The Windset investment was carried at a Level 3 fair value of $29.6 million. Its valuation depends on unobservable cash-flow, growth and discount-rate assumptions; a 10% increase in discount rates was estimated to reduce value by approximately $0.9 million.
- Goodwill and other indefinite-lived intangible assets totaled approximately $98.0 million. No impairment was recorded, but the impairment analyses depend on management’s projections and discount rates.
- Contractual obligations totaled approximately $60.3 million, including $44.3 million of debt principal, $6.7 million of interest, $7.3 million of operating leases and $2.0 million of purchase commitments.
- The filing reports no material legal proceedings and no dividends on common stock.
Important Facts for Investors to Verify
- Confirm the correct issuer and period: the filing is Landec Corporation FY2013, not Lifecore Biomedical FY2012 Q4.
- Assess the sustainability of earnings excluding the $8.1 million Windset fair-value gain and $3.9 million GreenLine earn-out reversal.
- Review GreenLine integration, customer retention, cross-selling results and the effect of weather-related sourcing costs on normalized margins.
- Reconcile cash generation with debt maturities, capital expenditures and the company’s stated twelve-month liquidity assessment.
- Examine the valuation sensitivity of the $29.6 million Windset investment and the approximately $49.6 million goodwill balance.
- Monitor customer concentration, single-source suppliers, regulatory approvals and the status of remediated internal controls.